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Adoptive transfer of T-cell-receptor (TCR)-transduced T cells has shown promising results for cancer treatment,
but has also produced severe immunotoxicities caused by on-target as well as off-target TCR recognition. Off-
target toxicities are related to the ability of a single T cell to cross-recognize and respond to several different
peptide–major histocompatibility complex (pMHC) antigens; a property that is essential for providing broad
antigenic coverage despite a conﬁned number of unique TCRs in the human body. However, this degeneracy
makes it incredibly difﬁcult to account for the range of targets that any TCR might recognize, which represents a
major challenge for the clinical development of therapeutic TCRs. The prospect of using afﬁnity-optimized TCRs
has been impeded due to observations that afﬁnity enhancement might alter the speciﬁcity of a TCR, thereby
increasing the risk that it will cross-recognize endogenous tissue. Strategies for selecting safe TCRs for the clinic
have included functional assessment after individual incubations with tissue-derived primary cells or with pep-
tides substituted with single amino acids. However, these strategies have not been able to predict cross-
recognition sufﬁciently, leading to fatal cross-reactivity in clinical trials. Novel technologies have emerged that
enable extensive characterization of the exact interaction points of a TCR with pMHC, which provides a foun-
dation from which to make predictions of the cross-recognition potential of individual TCRs. This review de-
scribes current advances in strategies for dissecting the molecular interaction points of TCRs, focusing on their
potential as tools for predicting cross-recognition of TCRs in clinical development.Adoptive T-cell transfer
The ﬁeld of adoptive T-cell transfer was established with the thera-
peutic application of ex vivo expanded tumor inﬁltrating lymphocytes
that effectively mediate tumor regression when re-infused into patients
with cancer [1]. Despite the success of these treatments, which has been
widely demonstrated with impressive response rates of 20–50% [2–4],
their broad application has been impeded due to extensive production
time and limited commercial potential [5]. Importantly, the speciﬁcities
of such T-cell products are unknown, which makes it difﬁcult to predict
the outcome of treatment in individual patients. This has driven interest
in the development of T-cell therapies that are amenable for a broader
group of patients, such as the transfer of T cells transduced with a
chimeric antigen receptor [6,7] or a TCR that recognizes known
cancer-associated targets [8,9]. The proposal that TCR-based genedrup, Kemitorvet Building 204, r
ier Ltd on behalf of European Soctherapy of cancer would be feasible came from studies showing the
effective redirection of T-cell speciﬁcity through transduction with
αβTCR genes that could provide antiviral and antitumor immunity
[8–15]. Early trials that used the DMF4 TCR [16] or the DMF5 TCR [17],
which both target a human leukocyte antigen (HLA)-A0201 MART-1
melanoma peptide, revealed that a TCR with greater functional avidity
and higher afﬁnity towards its target seemed to have greater promise for
cancer treatment but also caused autotoxicities [17–19]. These studies
imply that successful TCR-based gene therapy is facilitated by transfer of
T cells expressing high-afﬁnity TCRs, which is also corroborated by early
studies correlating TCR binding afﬁnity with functional responses
[20–26]. This, in turn, has encouraged strategies for the design of
high-afﬁnity TCRs intended for adoptive cell transfer schemes [24,
27–29], but may simultaneously increase the risk for TCR
cross-recognition of endogenous tissue [30,31].oom 154, 2800 Kgs. Lyngby, Denmark. Phone: þ45 35 88 62 90.
iety for Medical Oncology. This is an open access article under the CC BY-NC-ND
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selected for their ability to recognize shared cancer antigens; however,
for TCRs targeting foreign antigens, such as viral or neoantigens, which
are expected to be of higher afﬁnity, the need for such engineering may
be obviated.
Cross-reactivity
Several trials have been initiated to evaluate the safety and efﬁcacy of
adoptive transfer of TCR-transduced T cells [16,17,32–37]. Although the
strategy seems extremely attractive for treating various cancers effec-
tively with an ‘off-the-shelf’ T-cell product to be used across patients with
the same HLA haplotype, the occurrences of immunotoxicity have chal-
lenged the development of such treatment strategies. In particular, two
clinical trials highlight the need to approach the use of TCRs with
extreme care. The ﬁrst trial applied a high-avidity TCR generated from
vaccinated HLA-A0201 transgenic mice that targeted a melanoma
antigen-encoding-A3 (MAGE-A3)-derived peptide. Of nine enrolled pa-
tients, ﬁve had objective clinical responses; however, three experienced
neurological toxicity and two eventually died [38]. The toxicities were
subsequently explained by the ability of the TCR to cross-recognize a
related peptide, derived from MAGE-A12, which is expressed in the
human brain. This peptide only varies at the position 2 anchor residue,
and might therefore indicate that although natural TCRs should not
target healthy tissue, the strategies applied in adoptive cell therapymight
override peripheral tolerance mechanisms [39]. The second trial applied
a TCR targeting a MAGE-A3-derived peptide that binds HLA-A0101 [30].
The TCR had been obtained from a vaccinated patient [40,41] and
engineered to obtain higher afﬁnity [24]. Two patients were treated in
this trial, and both developed cardiac arrest and died shortly after T-cell
infusion. Extensive investigations revealed that despite a restricted
sequence similarity with the MAGE-A3 peptide (55% sequence overlap),
the TCR had cross-reacted with the protein, titin, which is expressed in
beating cardiomyocytes (Figure 1A) [30].Figure 1. T-cell receptor (TCR) degeneracy. (A) Engineering of a TCR targeting a M
afﬁnity resulted in cross-reactivity of a peptide (ESDPIVAQY) derived from the pro
broader antigenic coverage than if each TCR only recognized one epitope. Moreover,
TCRs, which reduces the risk that a virus or malignancy will produce escape varian
2TCR binding degeneracy
Extrapolations from experimental data estimate that a single TCR can
recognize at least 106 different MHC-bound peptides [42], which is
crucial for immunological protection of virtually all encountered patho-
gens and cellular malignancies [43–45]. Such TCR degeneracy is neces-
sary because if each TCR could recognize only one target, the number of
required single naïve T cells carrying a different TCR would far exceed
the number of cells of the human body [44,46] (Figure 1B). Reﬂecting on
the peptide targets of CD8 T cells (a sequence of eight to 14 amino acids
[47,48]), the total number of different peptides that could theoretically
be generated from the 20 naturally occurring amino acids would exceed
1018 [43]. Moreover, this does not account for post-translational modi-
ﬁcations, which are believed to alter peptides sufﬁciently to generate an
even greater number of T-cell targets [49–57]. Although this will be
reduced to only a few percent (1–3%) when accounting for peptide
processing and HLA presentation [44,58,59], it still amounts to an
astounding number of potential peptides that our TCR repertoire are able
to recognize to protect against pathogens of any type. The advantage of
having a conﬁned repertoire of highly cross-reactive TCRs is that various
clonal T cells can respond to a given pathogenic pMHC [43]. This reduces
the risk that pathogens will produce escape variants, as a single mutation
in a peptide sequence is unlikely to bypass recognition by several
different TCRs that could recognize the original pMHC [60,61].
Individual TCRs are generated through somatic recombination of
V(D) and J gene segments in developing T cells, and are clonally selected
before they develop into mature T cells. This produces a repertoire of
TCRs that can interact speciﬁcally with targets that are formed as
randomly as the range of pathogenic peptides, while not responding
inappropriately to self. However, the dual nature of the TCR recognition
motif, comprised of both peptide and MHC, represents an inherent
challenge for speciﬁc recognition as only a small area of the peptide is
exposed for direct contact with a TCR. Thus, much of the T-cell speciﬁcity
is conferred by the more invariant interaction with MHC, which explainsAGE-A3-derived peptide (EVDPIGHLY) that binds HLA-A0101 to obtain higher
tein, titin, expressed in beating cardiomyocytes. (B) TCR degeneracy provides
each peptide–major histocompatibility complex (pMHC) is recognized by several
ts.
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same MHC haplotype [62,63], while rarely being cross-reactive between
MHC haplotypes [64,65]. It has been reported that TCRs that require a
lower number of direct peptide interactions will have a greater binding
degeneracy in terms of the number of different pMHCs that they may
recognize [63,66,67]. Such promiscuity enables T cells to respond to a
large variety of target peptides, and allows recognition of peptides with
minimal sequence overlap [68,69].
Implications for immune therapy
The extent of TCR binding degeneracy is corroborated through
studies providing evidence of structural ﬂexibility of TCR–pMHC in-
teractions [61,70–79], and the continuous emergence of new examples
of clonal T cells recognizing peptides of varying sequence homology [30,
42,63,67,80–85]. These studies emphasize that although TCRFigure 2. Overview of the main experimental strategies to describe the cross-recog
strategy (CPL). The 51011 peptides of the CPL are distributed in 180 different poo
while the remaining eight positions comprise a random equimolar composition of a
comprises a new peptide pool for each of the 20 naturally occurring amino acids at
functional interrogation reveals the binding preferences of the given TCR. (B) The ye
complexes (pMHCs) are diversiﬁed through the use of mutagenic primers. This produc
leukocyte antigen. A tetramerized TCR of interest is incubated with the pooled lib
peptide sequences expressed by the yeast-displaying cells are recovered through deep
MHC multimers are produced from peptide variants of a known target. The variants
with the remaining 19 naturally occurring amino acids, which produce ~200 differen
labelled with a unique DNA barcode, and the total pool of multimers can be incuba
multimers in a hierarchy governed by the TCR–pMHC afﬁnity, which is reﬂected in
3cross-reactivity is essential for providing effective immunological sur-
veillance [44], it is also implicated in the development of autoimmune
diseases [66,86–89], and represents a major challenge for the develop-
ment of new TCR-based therapeutics. Currently, much concern is asso-
ciated with the potential cross-reactivity of afﬁnity-optimized TCRs as
these TCRs have not been through clonal selection. However, due to the
extensive binding degeneracy inherent in all TCRs, both endogenous and
modiﬁed TCRs may lead to cross-reactivity of healthy tissue when
applied in adoptive cell therapy, where peripheral tolerance mechanisms
are revoked. Consequently, critical adverse events may arise from the use
of natural TCRs [39]. Technologies are emerging which enable extensive
characterization of the patterns decisive for TCR engagement [67,
90–96], along with the prospects of describing and understanding some
of the elementary relationships between antigen speciﬁcity and the
cross-recognition potential of a TCR [97].nition potential of T-cell receptors (TCRs). (A) The 9mer combinatorial peptide
ls. Each pool contains one speciﬁc amino acid at a ﬁxed position (blue circles),
ll other naturally occurring amino acids except cysteine (grey circles). The CPL
each position. T cells are incubated with each peptide pool, and a subsequent
ast display strategy. Gene constructs encoding peptide–major histocompatibility
es a library of ~108 different peptides presented in the context of a given human
rary of pMHC-displaying yeast cells, and the interacting cells are isolated. The
sequencing of the isolated yeast cells. (C) DNA barcode-labelled MHC multimers.
comprise the peptides generated from sequentially substituting each amino acid
t peptides from an original 9–11mer peptide. Each MHC multimer is individually
ted with a T-cell clone or TCR-transduced T cells. The clonal TCR will bind the
the hierarchy of DNA barcode reads after sequencing.
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The initial safety evaluation of the afﬁnity-optimized MAGE-A3/titin
cross-reactive TCR (a3a), which proved incapable of identifying potential
toxicities despite thorough ‘speciﬁcity testing’ against primary cells from
a broad range of normal tissue, illustrates the need for technologies that
can effectively assess the cross-recognition potential of TCRs. Ideally,
their approach of assessing T-cell reactivity towards numerous cells and
tissue types would be the optimal way of determining biologically rele-
vant cross-reactivity, as this also accounts for antigen presentation and
post-translational modiﬁcations. However, this would require testing of
all tissue types within all stages of development, which is not feasible at
present. In the case of the a3a TCR, it was only after the observed fa-
talities that actively beating cardiomyocyte cell cultures were investi-
gated more extensively, and reactivity was discovered towards this
tissue. After careful examination of the TCR speciﬁcity, the authors
identiﬁed the cross-recognized titin-derived peptide–HLA-A0101-target
[30]. Several such approaches have since been developed, summarized in
Figure 2 and Table 1. Collectively, these aim to determine the exact
amino acids at given positions of the peptide sequence that are required
for TCR recognition, which, when correlated with knowledge of the
entire human proteome and potential HLA presentation, provides a
valuable strategy for predicting cross-recognition and hence potential
cross-reactivity.
Combinatorial peptide libraries
One such approach to identify the amino acid requirements for TCR
recognition, which have been adapted to several laboratories, utilizes
large combinatorial peptide libraries (CPLs) [42,92,98,99]. The peptides
are synthesized such that one position of a 9mer peptide is ﬁxed, while
the rest is composed of stochastic equimolar distribution of all naturally
occurring amino acids, except cysteine. The ﬁxed positions are
exchanged sequentially so that the complete pool of peptides contains all
20 naturally occurring amino acids at all ﬁxed positions, and T-cell
recognition is assessed based on functional interrogation of T cells
expressing a clonal TCR after exposure to individual peptide pools. The
absence of T-cell reactivity will thus reﬂect the requirement for a
different amino acid at the ﬁxed position, and collectively the data can
inform on those amino acids and positions that are essential for TCR
interaction. The assay also enables interrogation of how changing vari-
ables, such as presence or absence of the CD8 co-receptor, will affectTable 1
Strategies for resolving the recognition motif of T-cell receptors (TCRs)
Method Readout Require a pre-
established
TCR epitope
HLA availability
Combinatorial
peptide library
Functional readout that
reﬂects the amino acid
requirement one
position at a time
No Independent
Yeast displaya Quantitative readout
based on mutual epitope
competition. All
positions analysed in
one reaction
No New yeast display
library required for
every new HLA.
Currently only
developed for a few
HLAs
DNA barcode-
labeled MHC
multimers
Quantitative readout
based on mutual epitope
competition. All
positions analysed in
one reaction
Yes Possible for all foldable
HLAs. Currently ~35
The methods listed have been applied to understand the molecular interaction points
HLA, human leukocyte antigen; pMHC, peptide–major histocompatibility complex.
a The strategies reported in References 93–96, which have been applied to disc
recognition motif. Such implementation will share many characteristics with the yea
4functionality [92]. The CPL strategy requires large amounts of
TCR-expressing cells to be included in each individual pool, which is
feasible when investigating TCR-transduced T cells. However, assays that
require fewer cells would be valuable for early assessment of potential
cross-recognition, providing an initial selection criterion to ensure that
those TCRs with the greatest risk of cross-recognizing endogenously
derived peptides are excluded at an early stage. Moreover, because the
interrogation is based on a functional readout derived from recognition
of individual peptide pools, it does not provide a relative hierarchy of the
interactions, but rather a binary (yes or no) answer to the importance of
the different amino acid positions.
Peptide–MHC display and target cell selection
Another approach that provides a more accurate description of the
TCR binding degeneracy, because it relates to direct pMHC–TCR in-
teractions, applies a yeast display system where the pMHCs are encoded
in gene constructs with a linker between the peptide and the MHC
molecule [90]. This enables the generation of a random peptide sequence
through the use of mutagenic primers that produce degenerate codons,
allowing all 20 naturally occurring amino acids. pMHCs displaying yeast
cells are probed with tetramerized TCRs of interest, and interacting cells
are isolated through rounds of magnetic bead enrichment and
ﬂuorescence-activated cell sorting. Subsequent sequencing informs about
the peptide sequence expressed by the enriched yeast-displaying cells,
and thus reveals the TCRs' amino acid requirements for interaction with
pMHCs. The great advantage of this strategy, enabled by the random
formation of an incredible number of peptides, is associated with the
ability to perform largely unbiased screens, and is illustrated by the
identiﬁcation of pMHC targets of TCRs with otherwise unknown speci-
ﬁcities [100]. Moreover, a recent study has interrogated the a3a TCR
using the methodology on an HLA-0101 yeast display library. From the
TCR recognition pattern, it is evident that the amino acids at positions 3,
4 and 9 comprise the main interaction points with the receptor. This can
help explain the observed cross-recognition between the MAGE-A3- and
titin-derived peptides, as these positions are all shared between the
peptides [101]. Disadvantages of the technique are associated with the
inability to equally display all positions of the peptide sequence, and
cover all peptide variants. Furthermore, to date, the system has only been
developed for a few MHC molecules and is restricted to specialized lab-
oratories. A related strategy, based on a mammalian display system,
utilizes a minigene-based approach to encode peptide ligands of MHC-IReﬂects natural
peptide–HLA
binding
Disadvantages Advantages First
reported
Yes No direct measure of the
relative importance of
each peptide position
Can include
variables and
synthetic
molecules, e.g.
peptide mimetics
[92]
Moderately Peptide positions may not
be equally well
represented. Method
restricted to a few
specialized laboratories
Unbiased screening
based on direct
pMHC recognition
[90]
Marginally New peptide library
required for each analysed
pMHC speciﬁcity
Easy to implement
in laboratories
working with MHC
multimers
[67]
of TCRs, which can be used to estimate their cross-recognition potential.
over the antigen speciﬁcities of TCRs, also have the potential to resolve their
st display method.
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pooled screenings of TCR interactions with different pMHCs, and hence,
determination of potential cross-recognition [96].
A number of recently reported strategies for detecting T-cell antigens
[93–95] conceptually resemble the yeast display approach, but provide
an advantage because TCR interactions are determined from a cellular
system (either T-cell clones or TCR-transduced T cells), whereas the yeast
display strategy requires production of soluble TCRs for tetramerization.
Since these strategies enable the investigation of a large number of
different peptides, they have great potential for describing TCR binding
degeneracy, but have only been reported for detection of T-cell antigens
to date. One approach utilizes signaling and antigen-presenting bifunc-
tional receptors (SABRs), where a signaling domain has been introduced
to the MHC class I molecule, leading to green ﬂuorescent protein (GFP)
expression following pMHC–TCR engagement. Hence, interacting target
cells expressing a cognate antigen can be isolated based on GFP expres-
sion. Antigens applied in this system include large libraries of deﬁned
peptide sequences transduced into the NFAT-GFP-Jurkat cells together
with SABRs [94]. A similar strategy has been developed for MHC II an-
tigen presentation [95]. The ﬂexibility of these approaches allows for
customizations required for antigen discovery for public or private TCRs,
and can also be used to evaluate the breadth of recognition for a given
TCR. An alternative to the SABR approach, published by the same group,
takes advantage of a phenomenon known as ‘trogocytosis’, a process
whereby lymphocytes and target cells exchange surface molecules upon
TCR–pMHC engagement. When pMHC is expressed at supraphysiological
levels, this process occurs bi-directionally, hence transferring surface
molecules from T cells to the cells presenting a cognate epitope. This
marks the target cells, thereby enabling their isolation and, ultimately,
the discovery of the cognate TCR epitope. The process has been used for
discovery of the antigen speciﬁcity of orphan TCRs transduced into
Jurkat cells [93]. Like the SABR technique, this approach enables the
identiﬁcation of antigens expressed from large predeﬁned peptide li-
braries transduced into the target cells, and might become valuable for
assessing potential cross-recognition of TCRs.
TCR ﬁngerprinting using DNA barcode-labeled MHC multimers
We have recently developed a ‘one-pot’ tool for determining the
amino acid requirements at speciﬁc peptide positions for TCR recogni-
tion of pMHCs [67]. This method leverages DNA barcode-labeled MHC
multimers [102,103], which allows determination of the relative afﬁnity
of a clonal TCR to libraries of MHCs that carry peptides with substantial
sequence overlap. Peptide libraries are constructed from the originally
identiﬁed targets, and include all variants generated from sequentially
substituting each position with the 20 naturally occurring amino acids.
This generates libraries of approximately 200 peptide variants from an
original 9–11mer peptide. Individual DNA barcode-labeled MHC multi-
mers are generated from each peptide, and the multimers are pooled and
incubated with T cells expressing a clonal TCR. Sorting of all MHC
multimer-binding T cells and subsequent sequencing reveals a distribu-
tion of DNA barcode reads that reﬂects the pMHC–TCR binding hierar-
chy. The experimental design, which includes all amino acids at all
peptide positions, enables the translation of the binding hierarchy into a
positional scoring matrix for each TCR (Figure 3). This, in turn, is used to
determine the relative amino acid preferences of the TCR at individual
positions of the peptide sequence.
A disadvantage of the TCR ﬁngerprinting strategy relates to the
number of peptides included in a parallel screen. The strategy of
substituting a single amino acid position at a time underscores the pos-
sibility that several simultaneous amino acid substitutions might pro-
mote TCR interaction, or that a TCR might even be able to recognize a
largely different peptide [104,105]. Thus, an optimal assay would
include many more peptide variants to reﬂect the great variety of pMHC
targets that a TCR may potentially meet in vivo. However, this is not
feasible because peptide synthesis represents a considerable ﬁnancial5cost of the total MHC multimer analysis, and the strategy requires a new
peptide library for every new TCR that is interrogated. To investigate the
extent of this drawback, we interrogated one TCR using a larger peptide
library (~800 peptides) that included peptides with two simultaneous
amino acid substitutions, and obtained results that were comparable with
those obtained from substituting one position at a time. Having only
investigated the effect of multiple substitutions on one TCR, we cannot
conclude that simultaneous substitutions will never generate new pos-
sibilities for a TCR to interact, but the result implies that, for peptides
with some sequence overlap, single substitutions can potentially describe
most of the amino acids required for TCR interaction. Another drawback
relates to the need to have a pre-established peptide target of the inter-
rogated TCR fromwhich to construct the substitution library. Thus, in the
current embodiment of the strategy, it would not be possible to identify
new pMHC targets of TCRs with unknown speciﬁcities. Advantages
include ﬂexibility (in terms of the possibility of interrogating TCR
recognition restricted to all foldable MHC molecules) and a relatively
straightforward methodology, which should make it possible to imple-
ment the technology in most laboratories familiar with molecular biology
and MHC multimers. Moreover, the pooled format of the screening
provides a sensitive readout for speciﬁc TCR interactions that describe
the relative importance of the individual amino acids at each position in
the peptide.
An alternative use of DNA barcode-labeled MHC multimers, which
also addresses the issue of TCR cross-recognition, has enabled the
straightforward identiﬁcation of those TCRs responsive to a mutation-
derived neoepitope with the least risk of also cross-recognizing the
wild-type counterpart [106]. In this approach, one ﬂuorochrome is used
to label all DNA-encoded MHC multimers holding a neopeptide, and
another ﬂuorochrome is used for all the corresponding wild-type pep-
tides. T cells that cross-recognize both types of peptide will thus stain in
two colors. By single-cell sorting and capturing the TCR transcripts
associated with the single-color neoepitope-responsive T cells, the TCRs
with a lower risk of cross-recognizing wild-type peptides can be isolated,
while the simultaneously captured DNA barcode will inform on the exact
antigen speciﬁcities. The TCRs identiﬁed with such a methodology will
still require comprehensive analysis of the complete cross-recognition
potential before seeing therapeutic uses, but the strategy provides an
intelligent ﬁrst-selection criterion of neoepitope-responsive TCRs inten-
ded for the clinic.
Although all these strategies [combinatorial peptide libraries, pMHC
display strategies and DNA barcode-labeled MHC multimers (Figure 2)]
are advantageous compared with previous strategies that applied single-
position alanine or glycine substitutions [30], they are still experimen-
tally limited compared with the number of possible ligands that might be
encountered. Therefore, interpretations of the results should reﬂect that
it is merely a window of estimated cross-reactivity. Structural informa-
tion and in silico modeling [107,108] may, in turn, enhance the utility of
the experimental approaches for assessing TCR binding degeneracy.
Translating molecular interaction points of TCRs into cross-
recognition potential
Knowing the molecular interaction points of a TCR might assist the
identiﬁcation of cross-recognized peptides derived from endogenous
proteins, and hence provide a tool to assess the cross-recognition po-
tential of a given TCR before taking it to the clinic (Figure 3), ultimately
avoiding severe side-effects caused by TCR therapy. To assess this risk,
the knowledge acquired from dissecting the TCR interactions with pMHC
can be further analysed in silico, where a number of tools, including ﬁnd
individual motif occurrences [109] or ScanProsite [110], can be utilized
to identify peptide sequences in the human proteome that match the
molecular interaction points of a TCR, and hence are at risk of being
cross-recognized (Figure 3).
However, from the point of understanding TCR recognition and
predicting the potentially cross-recognized peptides using any of the
A.K. Bentzen, S.R. Hadrup Immuno-Oncology Technology 2 (2019) 1–10methods described in this review, further assessments are required to
determine whether such cross-recognition will pose an actual clinical
risk, as multiple mechanisms are in play controlling the ability of our
immune system's T cells to initiate cellular cytotoxicity. Important factors
to take into consideration include: (i) peptide processing and presenta-
tion; (ii) pMHC afﬁnity; (iii) protein expression level; and (iv) peripheral
tolerance mechanisms maintained by regulatory T cells, and surface
expressed and secreted molecules [111–115]. Peptide processing and
presentation in the context of patients' HLA molecules will substantiallyFigure 3. Schematic overview of the proposed strategy for e
6limit the number of potential peptides presented [58,59]. However,
prediction of antigen presentation is not trivial due to the many variables
involved in the processing machinery, and is, therefore, currently not
capable of sufﬁciently identifying the peptides that are truly presented.
The methods described in this review reﬂect differently on natural pre-
sentation of peptides; while the ability of peptide binding to MHC is an
integrated part of the CPL strategy, this method and the DNA
barcode-based methods do not reﬂect intracellular processing of longer
peptides. The methods utilizing antigen display to a larger degree reﬂectvaluation of T-cell receptor cross-recognition potential.
A.K. Bentzen, S.R. Hadrup Immuno-Oncology Technology 2 (2019) 1–10the processing of peptides, as the presented pMHCs are derived from
cellular systems.
A requirement for reaching a certain threshold of pMHC–TCR in-
teractions to activate a T cell means that T-cell recognition is only
translated into a functional response if the peptide is derived from a
protein expressed above a certain level [26], and is moreover inﬂuenced
by afﬁnity between the peptide and MHC [116]. Thus, TCR interaction
with a given pMHC does not necessarily correspond to T-cell reactivity,
which makes it important to distinguish between biochemical and
immunological recognition when considering potential toxicity of a TCR.
Consequently, the proﬁling of the TCR recognition motif to the human
genome should be used to guide researchers to identify tissues at risk,
which can be subjected to in-depth interrogation of functional T-cell
recognition to reveal whether T-cell recognition of an endogenously
derived peptide will lead to cellular destruction in vivo.
As several strategies of immune therapy of cancer, including adoptive
cell transfer strategies, work to deliberately break some level of tolerance
[117,118], it is not safe to assume that natural (non-modiﬁed) TCRs,
which have passed through clonal selection, will never target endoge-
nous tissue. Based on the 12 MCC clones investigated in the ﬁnger-
printing strategy [67], which target a Merkel cell polyomavirus-derived
peptide, these TCRs are non-modiﬁed and target an antigen that is
foreign to the immune system, but the data imply that most TCRs
cross-recognize peptides derived from healthy tissue. Currently, knowl-
edge of the extent and consequences of TCR cross-recognition are
insufﬁcient to predict when such cross-recognition will have an effect at a
functional level, and the potential of both natural and modiﬁed TCRs for
recognizing endogenously derived peptides should be examined carefully
prior to clinical translation.
Improving TCR design and optimization
Knowing the landscape of the cross-recognized pMHCs of individual
receptors has proven particularly important for the in vitro afﬁnity-
optimized TCRs developed for clinical applications. Due to the severe
adverse effects observedwith such genetically modiﬁed TCRs, and because
of the evidence that T-cell function is not enhanced above a certain
TCR–pMHC afﬁnity threshold [119–121], novel structure-guided ap-
proaches are concerned with the effect of modifying TCRs in a way that
ﬁnds an optimal (rather than maximum) TCR afﬁnity range [20,26,122,
123], and propose to incorporate changes that simultaneously enhance and
decrease the afﬁnity of the pMHC–TCR interaction [62]. It is suggested that
a TCRwithoptimal on-target (only) afﬁnitymaybegeneratedbymodifying
the TCR in a way that promotes stronger binding to the peptide part of the
TCR recognition motif while decreasing the overall binding toMHC [124].
Therefore, while all modiﬁcations of natural TCRs may pose a risk,
increasedmotivation for describing themolecular recognition patterns of a
TCR to assist the process of ‘rational design’ of genetically modiﬁed TCRs
intended for the clinic is emerging. Moreover, knowledge of the molecular
interaction points of TCRs can feed into developing in silico platforms,
increasing our overall capacity to understand TCR interactions and predict
T-cell cross-recognition. Taken together, such measures can be applied to
facilitate the generationof efﬁcient and safe TCRgene therapy strategies for
future treatment of advanced cancer.
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